The European Commission (EC) and the Medicines and Healthcare products Regulatory Agency (MHRA) have approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback